{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:02:28Z","timestamp":1793109748740,"version":"4.5.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T00:00:00Z","timestamp":1633305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Immune checkpoints inhibitors (ICPIs), as either a frontline or adjuvant therapy, showed favorable outcomes among diverse malignancies. Immune-related adverse events (IRAEs) are increasingly encountered, but the kidneys are rarely affected. A 67-year-old man with stage IV squamous cell carcinoma of the lung presented with acute kidney injury and hypercalcemia secondary to bone metastasis. After an aggressive saline infusion and subcutaneous denosumab 60mg administration, his renal function and serum calcium level were recovered on day 4. Due to his intolerance to chemotherapy, immunotherapy with a monoclonal antibody targeting programmed cell death protein-1 (PD-1), pembrolizumab 2mg\/kg, was used on day 4. On day 11, polyuria, non-albumin dominant proteinuria, and severe deficiencies of electrolytes (potassium 2.5 mmol\/L, calcium 5.5 mg\/dL, magnesium 1.3 mg\/dL, and phosphate 1.5 mg\/dL) along with concomitant renal wasting were developed acutely. Except for postponing the next pembrolizumab, prednisolone at 1 mg\/kg\/day was given on day 13. On day 27, his polyuria subsided and urine protein loss resolved. Serum levels of potassium, phosphate, calcium, and magnesium all returned within the reference range. This case highlighted that renal IRAEs, even though uncommon, could be severe and potentially life-threatening if left unrecognized and untreated. Early recognition of renal IRAEs and prompt withdrawal of ICPIs may result in lower renal morbidity.<\/jats:p>","DOI":"10.3389\/fmed.2021.742489","type":"journal-article","created":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T05:18:35Z","timestamp":1633324715000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Acute Diffuse Renal Tubulopathy in a Patient With Lung Cancer: A Case Report"],"prefix":"10.3389","volume":"8","author":[{"given":"Po-Jung","family":"Tseng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Tso","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.2174\/0929867324666170804143706","article-title":"Immune checkpoint inhibitors: basics and challenges","volume":"26","author":"Li","year":"2019","journal-title":"Curr Med Chem."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.ekir.2020.04.018","article-title":"Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events","volume":"5","author":"Herrmann","year":"2020","journal-title":"Kidney Int Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/ckj\/sfy100","article-title":"Renal toxicities associated with pembrolizumab","volume":"12","author":"Izzedine","year":"2019","journal-title":"Clin Kidney J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/eji.201646875","article-title":"Immune checkpoints and their inhibition in cancer and infectious diseases","volume":"47","author":"Dyck","year":"2017","journal-title":"Eur J Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"k793","DOI":"10.1136\/bmj.k793","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis","volume":"360","author":"Baxi","year":"2018","journal-title":"BMJ."},{"key":"B10","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000455014","article-title":"Adverse renal effects of immune checkpoint inhibitors: a narrative review","volume":"45","author":"Wanchoo","year":"2017","journal-title":"Am J Nephrol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.kint.2016.05.024","article-title":"Checkmate: kidney injury associated with targeted cancer immunotherapy","volume":"90","author":"Perazella","year":"2016","journal-title":"Kidney Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"8408015","DOI":"10.1155\/2018\/8408015","article-title":"Renal tubular acidosis an adverse effect of PD-1 inhibitor immunotherapy","volume":"2018","author":"El Bitar","year":"2018","journal-title":"Case Rep Oncol Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000380960","article-title":"Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5","volume":"41","author":"Dave","year":"2015","journal-title":"Am J Nephrol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40264-019-00888-1","article-title":"Drug-induced hypophosphatemia: current insights","volume":"43","author":"Megapanou","year":"2020","journal-title":"Drug Saf."},{"key":"B15","doi-asserted-by":"publisher","first-page":"871","DOI":"10.3390\/nu9080871","article-title":"Changes of bone-related minerals during DENOSUMAB administration in post-menopausal osteoporotic patients","volume":"9","author":"Suzuki","year":"2017","journal-title":"Nutrients."},{"key":"B16","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical Features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1681\/ASN.2018050488","article-title":"Nephrotoxicity of cancer immunotherapies: past, present and future","volume":"29","author":"Perazella","year":"2018","journal-title":"J Am Soc Nephrol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e1480301","DOI":"10.1080\/2162402X.2018.1480301","article-title":"An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer","volume":"7","author":"Liede","year":"2018","journal-title":"Oncoimmunology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature09707","article-title":"Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signaling","volume":"470","author":"Tan","year":"2011","journal-title":"Nature."},{"key":"B20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer."},{"key":"B21","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/ckj\/sfw024","article-title":"Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma","volume":"9","author":"Murakami","year":"2016","journal-title":"Clin Kidney J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients","volume":"68","author":"Shirali","year":"2016","journal-title":"Am J Kidney Dis."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.742489\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T05:18:43Z","timestamp":1633324723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.742489\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,4]]},"references-count":22,"alternative-id":["10.3389\/fmed.2021.742489"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.742489","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,4]]},"article-number":"742489"}}